Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence H Patterson

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Drug Metabolism Reviews|September 7, 2002
Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapyLaurence H Patterson
Current Medicinal Chemistry. Anti-Cancer Agents|September 24, 2004
Resistance in cancer: a target for drug discoveryMark Searcey, Laurence H Patterson
Current Topics in Medicinal Chemistry|October 27, 2005
DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agentsKlaus Pors, Laurence H Patterson
Journal of Medicinal Chemistry|February 27, 2014
Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonistsHelen M Sheldrake, Laurence H Patterson
Organic & Biomolecular Chemistry|October 11, 2016
Intramolecular thermal stepwise [2 + 2] cycloadditions: investigation of a stereoselective synthesis of [n.2.0]-bicyclolactonesAdam Throup, Laurence H Patterson, Helen M Sheldrake
IUBMB Life|May 2, 2022
Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs)Paul J Smith, Stephanie R McKeown, Laurence H Patterson
Proteomics|November 11, 2009
Improved preparation and detection of cytochrome P450 isoforms using MS methodsChris W Sutton, Mark Sutherland, Steve Shnyder, et al.
Cancers|June 8, 2017
RGD-Binding Integrins in Head and Neck CancersHanadi Talal Ahmedah, Laurence H Patterson, Steven D Shnyder, et al.
Methods and Protocols|July 23, 2025
K562 Chronic Myeloid Leukemia Cells as a Dual β3-Expressing Functional Cell Line Model to Investigate the Effects of Combined αIIbβ3 and αvβ3 AntagonismAmal A Elsharif, Laurence H Patterson, Steven D Shnyder, et al.
Molecular & Cellular Proteomics : MCP|February 14, 2007
Comparative cytochrome P450 proteomics in the livers of immunodeficient mice using 18O stable isotope labelingCatherine S Lane, Yuqin Wang, Richard Betts, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Drug Metabolism Reviews|September 7, 2002
Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapyLaurence H Patterson
Current Medicinal Chemistry. Anti-Cancer Agents|September 24, 2004
Resistance in cancer: a target for drug discoveryMark Searcey, Laurence H Patterson
Current Topics in Medicinal Chemistry|October 27, 2005
DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agentsKlaus Pors, Laurence H Patterson
Journal of Medicinal Chemistry|February 27, 2014
Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonistsHelen M Sheldrake, Laurence H Patterson
Organic & Biomolecular Chemistry|October 11, 2016
Intramolecular thermal stepwise [2 + 2] cycloadditions: investigation of a stereoselective synthesis of [n.2.0]-bicyclolactonesAdam Throup, Laurence H Patterson, Helen M Sheldrake
IUBMB Life|May 2, 2022
Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs)Paul J Smith, Stephanie R McKeown, Laurence H Patterson
Proteomics|November 11, 2009
Improved preparation and detection of cytochrome P450 isoforms using MS methodsChris W Sutton, Mark Sutherland, Steve Shnyder, et al.
Cancers|June 8, 2017
RGD-Binding Integrins in Head and Neck CancersHanadi Talal Ahmedah, Laurence H Patterson, Steven D Shnyder, et al.
Methods and Protocols|July 23, 2025
K562 Chronic Myeloid Leukemia Cells as a Dual β3-Expressing Functional Cell Line Model to Investigate the Effects of Combined αIIbβ3 and αvβ3 AntagonismAmal A Elsharif, Laurence H Patterson, Steven D Shnyder, et al.
Molecular & Cellular Proteomics : MCP|February 14, 2007
Comparative cytochrome P450 proteomics in the livers of immunodeficient mice using 18O stable isotope labelingCatherine S Lane, Yuqin Wang, Richard Betts, et al.
Pageof 6